Abstract:The Unfolded Protein Response (UPR) is a cascade of intracellular stress signaling from the endoplasmic reticulum (ER) that protect the cells from the stress caused by accumulation of unfolded or misfolded proteins in the ER. Activating transcription factor 6 (ATF6) is one of primary UPR transducers that remodels the stressed cells through transcriptional regulation. Although the activation mechanism and biological roles of ATF6 have been well studied, the understanding of the negative or feedback regulation of ATF6 remains elusive. In this report, we showed that ATF6 protein can be modified by small ubiquitin-like modification (SUMOylation) and that the transcriptional activity of ATF6 is negatively regulated by SUMOylation. We identified that SUMOylation of ATF6 is significantly increased in the cells expressing misfolded cystic fibrosis transmembrane conductance regulator (CFTR) encoded by the mutant human CFTR gene (dF508CFTR). Further analyses revealed two highly conserved SUMOylation motifs within the trans-activation domain of ATF6 protein of human, mouse, or rat specie. The human ATF6 protein can be SUMOylated mediated through the small ubiquitin-like modifier protein 1 (SUMO-1) and E3 SUMO-protein ligase 1 (PIAS1) at the conserved sumoylation residue Lys149 that is located at the N-terminal of the activated form of ATF6 protein. Bimolecular fluorescence complementation (BiFC) analysis confirmed that the activated ATF6 protein can be SUMOylated and that the ATF6 sumoylation occurs in the nuclei. Moreover, trans-activation reporter analysis demonstrated that SUMOylation of the ATF6 protein at the conserved residue Lys149 represses the transcriptional activity of ATF6. In summary, our study revealed a negative regulation of the UPR transducer ATF6 through post-translational SUMOylation. The information from this study will not only increase our understanding of the fine-tuning regulation of the UPR signaling but will also be informative to the modulation of the UPR for therapeutic benefits.

The ubiquitin-like modifier FAT10 interferes with SUMO activation

Advance in the Research of the Ubiquitin-Like Molecule FAT10

Nub1 traps unfolded FAT10 for ubiquitin-independent degradation by the 26S proteasome

Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation

A Proteomics Strategy for the Identification of Fat10-Modified Sites by Mass Spectrometry

Characterization of the Covalent Binding Ability of FAT10 to Protein Substrates

FAT10: Function and Relationship with Cancer

SUMOylation Activates Large Tumour Suppressor 1 to Maintain the Tissue Homeostasis During Hippo Signalling

SUMOylation of Large Tumor Suppressor 1 at Lys751 Attenuates Its Kinase Activity and Tumor-Suppressor Functions

Ubiquitin‑like Protein FAT10 Regulates DNA Damage Repair Via Modification of Proliferating Cell Nuclear Antigen.

SUMOylation Represses the Transcriptional Activity of the Unfolded Protein Response Transducer ATF6.

SUMO’s intrinsically disordered N-terminus is an intramolecular inhibitor of SUMO - SIM interactions

The Thermodynamic Properties of Fat10ylated Proteins Are Regulated by the Fat10ylation Site

Ubiquitin-like Protein FAT10 Suppresses SIRT1-mediated Autophagy to Protect Against Ischemic Myocardial Injury

Pharmacological inhibition of SUMOylation recapitulates genetic hypoSUMOylation in the murine epididymal white adipose tissue

Crystal structures reveal catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6

Ube1dc1, an Ubiquitin-Activating Enzyme, Activates Two Different Ubiquitin-Like Proteins

SUMO conjugation – a mechanistic view

Interplay Between Ubiquitylation and SUMOylation: Empowered by Phase Separation

The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy

Concerted SUMO-targeted ubiquitin ligase activities of TOPORS and RNF4 are essential for stress management and cell proliferation